FibroGen Inc (NASDAQ: FGEN) is -64.71% lower on its value in year-to-date trading and has touched a low of $0.29 and a high of $2.93 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FGEN stock was last observed hovering at around $0.31 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.31, the stock is -6.47% and -15.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.99 million and changing 0.77% at the moment leaves the stock -71.32% off its SMA200. FGEN registered -43.37% loss for a year compared to 6-month loss of -74.36%. The firm has a 50-day simple moving average (SMA 50) of $0.36946 and a 200-day simple moving average (SMA200) of $1.09405.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.55% gain in the last 1 month and extending the period to 3 months gives it a -23.52%, and is 3.78% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.40% over the week and 8.51% over the month.
FibroGen Inc (FGEN) has around 486 employees, a market worth around $31.40M and $173.81M in sales. Profit margin for the company is -96.84%. Distance from 52-week low is 7.86% and -89.32% from its 52-week high.
FibroGen Inc quarterly earnings per share for the current quarter are estimated at -0.3 with sales reaching $34.76M over the same period.The EPS is expected to grow by 65.03% this year, but quarterly earnings will post 18.10% year-over-year. Quarterly sales are estimated to shrink -13.40% in year-over-year returns.
120.0 institutions hold shares in FibroGen Inc (FGEN), with institutional investors hold 57.59% of the company’s shares. The shares outstanding are 98.77M, and float is at 93.37M with Short Float at 4.32%. Institutions hold 57.10% of the Float.
The top institutional shareholder in the company is PRIMECAP MANAGEMENT CO/CA/ with over 13.66 million shares valued at $12.19 million. The investor’s holdings represent 13.7964 of the FGEN Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 8.94 million shares valued at $7.97 million to account for 9.0279 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 5.89 million shares representing 5.9458 and valued at over $5.25 million, while ACADIAN ASSET MANAGEMENT LLC holds 3.3993 of the shares totaling 3.36 million with a market value of $3.0 million.
FibroGen Inc (FGEN) Insider Activity
The most recent transaction is an insider purchase by Adib Deyaa, the company’s Chief Medical Officer. SEC filings show that Adib Deyaa bought 22,123 shares of the company’s common stock on Jun 12 ’24 at a price of $1.17 per share for a total of $25884.0. Following the purchase, the insider now owns 82123.0 shares.
FibroGen Inc disclosed in a document filed with the SEC on Mar 07 ’24 that Wettig Thane (CEO) bought a total of 50,000 shares of the company’s common stock. The trade occurred on Mar 07 ’24 and was made at $1.91 per share for $95470.0. Following the transaction, the insider now directly holds 0.47 million shares of the FGEN stock.
